Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

Comparison Between Ultrasound-Guided Genicular Nerve Phenol Neurolysis and Intra-articular Steroid Injections

Phase 4

Not yet recruiting

Conditions: Chronic Knee Pain
Osteoarthritis, Knee

Interventions: Drug: 6% aqueous phenol
Drug: MethylPREDNISolone 40 MG
Drug: Genicular Nerve Placebo
Drug: Intraarticular Knee Placebo

First Posted Date: 2023-08-21

Last Posted Date: 2023-10-10

Lead Sponsor: University of Manitoba

Target Recruit Count: 40

Registration Number: NCT06000709

Methylprednisolone in Patients with Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

Phase 2

Recruiting

Conditions: Post-COVID-19 Syndrome

Interventions: Drug: Methylprednisolone

First Posted Date: 2023-08-14

Last Posted Date: 2025-02-19

Lead Sponsor: Charite University, Berlin, Germany

Target Recruit Count: 418

Registration Number: NCT05986422

Locations: 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany

Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.

Completed

Conditions: Cerebral Venous Thrombosis

Interventions: Drug: Methylprednisolone

First Posted Date: 2023-08-14

Last Posted Date: 2024-08-20

Lead Sponsor: Xuanwu Hospital, Beijing

Target Recruit Count: 170

Registration Number: NCT05990894

Locations: 🇨🇳
Xuanwu Hospital, Capital Medical University, Beijing, China

MYTHS-MR Trial (MYocarditis THerapy With Steroids in Patients With Mildly Reduced Ejection Fraction)

Phase 3

Recruiting

Conditions: Acute Myocarditis

Interventions: Drug: Methylprednisolone 125 MG
Other: IV saline solution 0.9%

First Posted Date: 2023-08-03

Last Posted Date: 2025-04-17

Lead Sponsor: University Hospital, Antwerp

Target Recruit Count: 174

Registration Number: NCT05974462

Locations: 🇧🇪
Universitair ziekenhuis Leuven, Leuven, Belgium
🇮🇹
Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
🇮🇹
Careggi University Hospital, Firenze, Italy

and more 16 locations

The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin

Phase 2

Completed

Conditions: Odontogenic Infection of Jaw (Disorder)

Interventions: Drug: Methylprednisolone

First Posted Date: 2023-07-19

Last Posted Date: 2023-07-21

Lead Sponsor: University of Manitoba

Target Recruit Count: 29

Registration Number: NCT05951504

Locations: 🇨🇦
University of Manitoba, Winnipeg, Manitoba, Canada

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

Phase 3

Recruiting

Conditions: Colitis

Interventions: Drug: Infliximab
Drug: Methylprednisolone
Drug: Prednisolone

First Posted Date: 2023-07-17

Last Posted Date: 2023-08-24

Lead Sponsor: Odense University Hospital

Target Recruit Count: 195

Registration Number: NCT05947669

Locations: 🇬🇧
The Royal Marsden Hospital, London, United Kingdom
🇩🇰
Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
🇩🇰
Department of Oncology Odense University Hospital, Odense, Denmark